Inactive

NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: BioRad XQ200 Droplet Generator 1. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpar... NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: BioRad XQ200 Droplet Generator 1. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. 2. The solicitation number is 75N95021Q00387 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures and FAR Part 12—Acquisition of Commercial Items and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Among the goals of the agency are to develop, maintain, and renew scientific human and physical resources to ensure a continued high return on the public investment in research, and to exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science. In realizing these goals, the NIH provides leadership and direction to programs designed to improve the health of the Nation by conducting and supporting research in various areas. The National Institute of Neurological Disorders and Stroke (NINDS) was established to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people. Different viruses have been associated with diseases of the central nervous system including multiple sclerosis (MS), encephalitis, epilepsy. The concentration of those viruses in clinical samples can vary and its detection is dependent on Polymerase Chain Reaction (PCR) sensitivity and subject to high inter-replicate variance. The XQ200 droplet generator is a third-generation technology that follows after Nested PCR and real time PCR. Nested PCR has proven to be a valuable tool for detecting low frequency events; however, it is not quantitative and is highly prone to false positive signals. The real time PCR is quantitative, although its accuracy is limited by the need for an external calibrator. XQ200 droplet generator is a new, non-nested digital PCR technology that has recently emerged and that enables absolute quantification offering an extraordinarily high degree of precision. In digital PCR, DNA is distributed across multiple replicate reactions. These replicates enable the use of Poisson statistics for absolute quantification. Pursuant to FAR Subpart 13.501(a)(1)(iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. 3. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2021-07 dated August 11, 2021 4. The associated NAICS code is 334516 and the small business size standard is 1,000 employees. No set-aside restriction is applicable. 5. This solicitation. is for the acquisition of a Droplet Generator, BioRad, XQ200, Part Number 1864002 and an on-site Service Contract Agreement for the Droplet Generator. See Attachment 1 - Product Description for additional details and specifications. The items to be procured include: Line Item 1 - QX200™ Droplet Generator Droplet generator for EvaGreen or probe-based digital PCR applications, for use with QX200™ Droplet Digital™ PCR System. Quantity: 1. Line Item 2 - SCA, Droplet Generator add-on 1 Year, On-site Service Contract Agreement for QX Droplet Generator (must be purchased with QX system service agreement). Quantity: 1. 6. Delivery shall be to: The National Institute of Neurological Disorders and Stroke 10 Center Drive, Laboratory 5C103 Bethesda, MD 20814 Delivery Date: 30 days after receipt of order (ARO) The Contractor shall deliver the instrument to the NINDS laboratory 5C103 located at 10 Center Drive, Bethesda, MD 20814, within 30 days after receipt of order (ARO). The instrument shall be delivered between of hours of 9:00 AM and 4:00 PM Eastern Standard Time, Monday through Friday (except federal holidays). Delivery must be Freight on Board (FOB) Destination, including inside delivery to the room number specified. All required items shall be packaged, marked and shipped in accordance with Government specifications. At a minimum, they shall be marked with the contract number and Contractor name. 7. The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition. 8. The provision at FAR clause 52.212-2, Evaluation – Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. (b) Offers will be evaluated for technical criteria and price. Technical criteria consist of matching the line items identified above, ability to provide the equipment and deliver the equipment. Technical criteria, when combined, are significantly more important than price. (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. 9. Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Items, with offers. 10. The FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition. The following addendum applies: The following FAR provisions or clauses are incorporated by reference: 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) 11. Additional Attachments: Attachment 5: FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Items, applies to this acquisition. Attachment 3: Invoice and Payment Provisions (Rev. 2/10/2021) 12. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this solicitation must include enough information to establish the interested parties’ bona-fide capabilities of providing the product or service. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement. 13. The offeror must complete and return FAR 52.204-24 (OCT 2020) and FAR 52.204-26 (OCT 2020) Representations and Certifications with its offer if it is has not been completed and updated in SAM.gov. 14. Respondents proposing on an equal product of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. 15. In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. Fax responses will not be accepted. All responses must be received by September 15, 2021 at 1:00 PM Eastern Standard Time and reference solicitation number 75N95021Q00387. Responses must be submitted by email to Shaun Rostad, Contract Specialist, shaun.rostad@nih.gov, tel. 301-443-6677. The name of the individual to contact for information regarding the solicitation: Shaun Rostad, Contract Specialist, shaun.rostad@nih.gov. 16. Questions and requests for clarification should be submitted electronically to the Contract Specialist, Shaun Rostad at shaun.rostad@nih.gov on or before 1:00 pm September 13, 2021. Any questions or request for clarification must include the combined synopsis/solicitation 75N95021Q00387 and the Title in the Subject Line.

Inactive

DESCRIPTION: The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) and National Institutes of Health (NIH) is seeking Capability Statements from BOTH Other than Small Business ... DESCRIPTION: The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) and National Institutes of Health (NIH) is seeking Capability Statements from BOTH Other than Small Business and Small Business organizations with the demonstrated capability of providing service to support the NIDA-IRP Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit with Positron Emission Tomography compound radiosynthesis, the required instruments, supply of animals and housing of animals. This is a Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; (2) the availability of capable Small Businesses; HUBZone Small Businesses; Service-Disabled, Veteran-Owned Small Businesses; 8(a) Small Businesses; Veteran-Owned Small Businesses; Woman-Owned Small Businesses; or Small Disadvantaged Businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The established NAICS code is 334516, Analytical Laboratory Instrument Manufacturing. The U.S. Small Business Administration establishes a size standard for 334516 as 1,000 employees or less. BACKGROUND: The BioRad XQ200 droplet generator (brand name or equal) is part of the droplet digital PCR (ddPCR) system and provides absolute quantification of target DNA molecules. One of the goals of the laboratory is to study the association between viruses and neurological disorders. The droplet digital PCR system is a third-generation technology that, using water-in-oil droplets, increases the number of replicates up to 20,000 nanolites-sized droplets, enabling high specificity and sensitivity. Importantly, this particular instrument will replace the National Institute of Neurological Disorders and Stroke’s (NINDS) previous instrument and as such this specific model provide continuity on the same system which is key for NINDS’ research and for the accuracy and comparison of longitudinal clinical samples. PURPOSE AND OBJECTIVES: Different viruses have been associated with diseases of the central nervous system including multiple sclerosis (MS), encephalitis, epilepsy. The concentration of those viruses in clinical samples can vary and its detection is dependent on Polymerase Chain Reaction (PCR) sensitivity and subject to high inter-replicate variance. The XQ200 droplet generator (brand name or equal) is a third-generation technology that follows after Nested PCR and real time PCR. Nested PCR has proven to be a valuable tool for detecting low frequency events; however, it is not quantitative and is highly prone to false positive signals. The real time PCR is quantitative, although its accuracy is limited by the need for an external calibrator. XQ200 droplet generator is a new, non-nested digital PCR technology that has recently emerged and that enables absolute quantification offering an extraordinarily high degree of precision. In digital PCR, DNA is distributed across multiple replicate reactions. These replicates enable the use of Poisson statistics for absolute quantification. PURCHASE DESCRIPTION: One (1) Droplet Generator, BioRad, XQ200, Part Number 1864002 (brand name or equal) SALIENT CHARACTERISTICS: The BioRad XQ200 droplet generator is used to partition ddPCR reaction mix into thousands of nanoliter-sized droplets. After PCR on a thermal cycler, droplets from each sample are analyzed individually on the QX200 droplet reader. Droplets are read well by well. The PCR-positive and PCR-negative droplets are counted to provide absolute quantification of target DNA in digital form. This system can be designed using multiplex primers and probes that could clearly visualized coinfection of two different viruses or the same virus, but different variants, within a given sample. The high specificity and sensitivity of this system is what the NINDS laboratory is looking for in this instrument especially for the high throughput of clinical samples, from cerebrospinal fluid (CSF), peripheral blood cells (PBMC), saliva, serum, plasma and urine. INSTRUCTIONS: All capability statements must also include the following: 1) company name and address; 2) point of contact; 3) phone/fax/email; 4) NAICS Code(s); 5) business size and status; 6) capability information in response to the requirement and qualifications identified in this notice; and 7) type of small business your organization classifies itself as (i.e.: Women-Owned, HUBZone, etc.). Each capability statement must include the respondent’s DUNS number, organization name, and address. Each response should include the technical and administrative points of contact, including names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on August 27, 2021. The Subject line for the submission should include this Sources Sought Number and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).